Author:
Capra Marcelo,Martin Thomas,Moreau Philippe,Baker Ross,Pour Ludek,Min Chang-Ki,Leleu Xavier,Mohty Mohamad,Segura Marta Reinoso,Turgut Mehmet,LeBlanc Richard,Risse Marie-Laure,Malinge Laure,Schwab Sandrine,Dimopoulos Meletios
Abstract
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The Phase 3 IKEMA study (NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) vs Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献